Sugi Predict

Sugi Predict / Compounds / SCHEMBL12426382

SCHEMBL12426382

SCHEMBL12426382

CCOC(=O)C1=CN(C)c2cccc(SC(=O)N(C)C)c2C1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.66
▸ KDM4E B2RXH2 2/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ AGTR1 P30556 1/20 0.32
▸ MAPT P10636 3/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ TSHR P16473 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ ALOX12 P18054 1/20 0.31
▸ GAA P10253 2/20 0.30
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426384 0.79 ACHE (1.00) ACHE
SCHEMBL12426385 0.77 ACHE (0.80) ACHEKDM4ECA12CA1CA2
SCHEMBL12426463 0.76 ACHE (0.42) ACHEKDM4ECA12CA1CA2
SCHEMBL7281559 0.73 CA12 (0.50) KDM4ECA12CA1CA2CA7
SCHEMBL12426331 0.72 ACHE (0.57) ACHEKDM4ECYP1A2ALDH1A1MEN1
SCHEMBL12426409 0.72 ACHE (0.43) ACHEKDM4EALDH1A1MEN1KMT2A
SCHEMBL12426380 0.70 ACHE (0.72) ACHEKDM4EALDH1A1MEN1KMT2A
SCHEMBL19895799 0.69 TSHR (0.59) KDM4ECYP1A2ALDH1A1MEN1KMT2A
SCHEMBL12426379 0.68 ACHE (0.61) ACHEKDM4EALDH1A1MEN1KMT2A
SCHEMBL12426381 0.68 ACHE (0.72) ACHEKDM4EALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1868998-B1 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS VFP THERAPIES (FR) 2016-05-25 — — EP disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 — — US disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 — — US disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 — — US disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS NLN, SNCA, APP ACHE 17/4885KDM4E 1927/4885CA12 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.